Am­ryt boost as ri­val Ami­cus pulls EB drug

The Irish Times - Business - - MARKETS - DO­MINIC COYLE

Ir­ish group Am­ryt has be­come the fron­trun­ner in the race to find a treat­ment for epi­der­mol­y­sis bul­losa (EB), known as but­ter­fly dis­ease, which causes skin in mainly young pa­tients to blis­ter at the slight­est touch.

Ri­val Ami­cus Ther­a­peu­tics, which had been ahead of Am­ryt, has pulled its drug af­ter it failed to meet cer­tain tar­gets in a phase iii trial. Am­ryt, which started its trial ear­lier this year, is ex­pected to re­port in­terim data in the first half of 2018.

Good­body an­a­lyst An­drew Young said Am­ryt’s AP101 drug was a gel that only needs to be ap­plied when dress­ings are changed every three or four days, as rec­om­mended for EB pa­tients.

Ami­cus’s wa­ter-based cream re­quired pa­tients to change dress­ings daily and this may have been a fac­tor in its fail­ure.

Newspapers in English

Newspapers from Ireland

© PressReader. All rights reserved.